Biotechnology Reviews

In recent years, the landscape of cancer treatment has been profoundly reshaped by the emergence of immunotherapy strategies such as Chimeric Antigen Receptor T-cell (CAR-T) therapy and antibody engineering. These modalities represent two of the most promising fronts in the fight against cancer, leveraging the body’s immune system to recognize and destroy malignant cells. While CAR-T therapy involves reprogramming the patient's T cells to target tumor cells, antibody engineering focuses on creating highly specific antibodies that can bind to cancer-specific antigens and recruit immune effector functions. This article explores the interplay between these two technologies, highlighting how they complement each other and could potentially integrate to offer more effective cancer treatment solutions.

The conjugation of oligonucleotides with various ligands to enhance their delivery, stability, and specificity for targeted therapeutics has become a cornerstone in the development of next-generation molecular therapies. These ligands can facilitate targeted delivery to specific tissues, cells, or intracellular compartments, thereby improving the therapeutic index of oligonucleotides. Beyond cholesterol, folic acid, and spermine, a wide range of ligands have been explored for these purposes. Here's an overview of the classes and examples of ligands used in oligonucleotide conjugation.

Synthetic cells in biotechnology represent an innovative frontier where scientists design and construct cells or cell-like structures from scratch. These synthetic cells are designed to mimic the behavior of natural biological cells, performing specific functions such as protein synthesis, metabolism, and self-replication. The overarching goal is to use these cells in various applications, including medicine, research, and industry.

https://www.linkedin.com/pulse/synthetic-cells-design-methods-construction-luke-mclaughlin-m2j2f/?trackingId=TFKOFd3bTgGAkz3oY4JtJw%3D%3D

In the rapidly evolving landscape of biotechnology, synthetic biology emerges as a frontier with boundless potential, blending engineering with biology to reimagine solutions to some of our most persistent medical challenges. Among the most promising avenues within this field is the exploration of phage potential—viruses that can infect and replicate within bacterial cells. This exploration not only opens new pathways for treating antibiotic-resistant infections but also heralds a new era of precision medicine. As researchers harness the capabilities of synthetic biology to engineer phage viruses, we stand on the brink of revolutionizing how we combat bacterial diseases, paving the way for targeted therapies that could transform patient outcomes worldwide. This article delves into the intersection of synthetic biology and phage therapy, exploring how these microscopic predators could potentially be the key to unlocking a future free of antibiotic resistance.

Synthetic antibodies represent a burgeoning field in biotechnology, characterized by the design and production of antibody mimics that can be generated entirely in vitro. This eliminates the need for animal-derived antibodies, thus paving the way for more ethical, sustainable, and possibly more effective therapeutic and diagnostic tools. Synthetic antibodies encompass a broad spectrum of technologies, including recombinant antibodies, nucleic acid aptamers, and non-immunoglobulin protein scaffolds, which can be engineered for high affinity and specificity to virtually any desired antigen.

Oligonucleotide synthesis refers to the chemical process of creating short sequences of nucleotides, which are the building blocks of DNA and RNA. This process is fundamental in molecular biology, genetics, and biotechnology for various applications including diagnostics, therapeutics, and research.

Nanobodies, the smallest functional fragments of antibodies derived from camelids such as llamas and camels, are transforming our approach to diagnostics, therapeutics, and research. These single-domain antibodies, composed solely of the variable domain of heavy-chain antibodies (VHH), offer significant advantages over traditional antibodies, including greater stability, solubility, and the ability to access cryptic epitopes. This article explores the unique structure, production methods, and groundbreaking applications of nanobodies in science and medicine.

The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) system has been a groundbreaking tool in genetic engineering, offering precise modifications to DNA that can lead to advancements in medicine, agriculture, and more. However, there are other systems and technologies developed or being developed for gene editing and genetic manipulation, each with its own advantages and limitations.

Antisense oligonucleotides (ASOs) represent a pivotal advancement in molecular medicine, offering a powerful tool for modulating gene expression with precision and specificity. Through targeted intervention in genetic pathways, ASOs provide a therapeutic strategy for a myriad of diseases that were previously considered intractable at the genetic level. The design of ASOs involves a sophisticated array of strategies, each tailored to maximize efficacy, specificity, stability, and safety, and minimize off-target effects and toxicity.

Biotechnology Reviews mission is to be a knowledge bridge, providing articles covering cutting edge research and developments beyond mere headlines. Providing both the backbone and structural knowledge at all levels of interest to Biotechnology enthusiasts, professionals, investors and scientists.